Your search for non small cell lung cancer returned 19 results

Active Filters

Click on a filter below to refine your search. Remove a filter to broaden your search.

Mpr-drug-news remove
Steve Duffy remove
Home remove

Your search for non small cell lung cancer returned 19 results

Sort Results:

Relevant Recent
Drugs in the Pipeline

PARP Inhibitor Veliparib Gets Orphan Drug Status from FDA

AbbVie announced that the Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an investigational combination with chemotherapies or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
News

FDA Approves NSCLC Indication for Pembrolizumab

Pembrolizumab (Keytruda; Merck) has been approved by the Food and Drug Administration (FDA) to treat patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PD-L1 as determined by an FDA-approved test.
News

Similar Efficacy, Reduced AEs with Afatinib Dose Reduction in NSCLC

For patients with EGFR mutation-positive non-small cell lung cancer (NSCLC) being treated with afatinib, dosing may be reduced to decrease adverse events without any compromise in the treatment's efficacy. These are the findings of two new large Phase 3 trials.
Drugs in the Pipeline

FDA Grants Opdivo New Breakthrough Therapy Status

Bristol-Myers Squibb announced that the Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Opdivo (nivolumab), to potentially treat recurrent or metastic squamous cell carcinoma of the head and neck (SCCHN) after platinum based therapy.
Drugs in the Pipeline

FDA Grants Lorlatinib Breakthrough Therapy Designation for NSCLC

Pfizer has begun enrolling patients in a Phase 3 study of lorlatinib, called 'CROWN'. The trial will be an open-label randomized, two-arm study comparing lorlatinib to crizotinib in the first-line treatment of patients with metastatic ALK-positive NSCLC.
News

First Biosimilar For Cancer Treatment Approved

The approval was based on evidence from animal study data, human pharmacokinetic and pharmacodynamics data, and clinical immunogenicity data which demonstrated Mvasi is a biosimilar to Avastin.
Drugs in the Pipeline

Tecentriq Granted Priority Review for mUC Indication

Genentech announced that the Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq (atezolizumab)